EASL 2026 Reflections: Key takeaways in late-onset genetic cholestasis and Alagille syndrome
Dr Silvia Vilarinho and Dr Deepak Joshi reflect on the highlights from EASL Congress 2026, focusing on late‑onset genetic cholestasis and new insights in Alagille syndrome. They discuss the expanding role of genomic testing in adults, the move toward multidisciplinary Genetic Grand Rounds, and emerging IBAT‑targeted therapies and pregnancy data that are changing diagnosis and management.
Evolving therapeutic approaches in late-onset genetic cholestasis
Carola Dröge and Verena Keitel-Anselmino discuss IBAT inhibitor therapy in adults with hereditary BSEP-deficiency at EASL 2026.
Observational data show IBAT inhibitor promise for pruritus in late-onset PFIC and ICP
Real-world data show promise for IBAT inhibitor use in adults with late-onset PFIC and women with ICP.
Case series suggests IBAT inhibitor benefits in adults with hereditary BSEP deficiency
Clinical data suggest comparable IBAT inhibitor response for adults with hereditary BSEP deficiency as seen in pediatric trials.
AASLD 2025 Reflections: Key takeaways in primary sclerosing cholangitis
Dr Marlyn Mayo and Dr Andreas Kremer share key insights on primary sclerosing cholangitis from AASLD The Liver Meeting 2025, and explore the latest in therapeutic developments and symptomatology.
AASLD 2025 Reflections: Key takeaways in late-onset genetic cholestasis
Dr Silvia Vilarinho and Dr Deepak Joshi share the highlights from AASLD The Liver Meeting 2025, with an emphasis on late-onset genetic cholestasis, and offer quick insights into new data on the growing utility of genetic testing and expanding therapeutic implications.
AASLD 2025 Reflections: Key takeaways in primary biliary cholangitis
Dr Andreas Kremer and Dr Marlyn Mayo highlight key advances in primary biliary cholangitis from AASLD The Liver Meeting 2025, and provide quick insights into the latest data on next-generation therapies.
Maralixibat offers clinically meaningful pruritus reductions in PSC
A real-world analysis of PSC patients given maralixibat suggests it offers meaningful improvements in pruritus.
Genetic etiology may explain majority of adult-onset cholestatic disorders
Most cases of unexplained cholestasis in adults have an identifiable underlying genetic cause.
Volixibat improves fatigue and sleep in PBC alongside pruritus
An analysis of trial data indicates that, alongside reducing pruritus, volixibat helps normalize fatigue and sleep in PBC patients.
Gene mutations linked to adult cholestasis
Mitchell Shiffman discusses the value of genetic testing in adults with undefined cholestasis.
Pharmacodynamic findings support linerixibat pruritus benefits in patients with PBC
Andreas Kremer explains post-hoc analysis findings from the phase 3 GLISTEN trial showing an effect of linerixibat on biomarkers and mediators of pruritus in patients with PBC.
IBAT inhibitors may improve post-liver transplant pruritus
Treatment-refractory pruritus following liver transplant may be successfully treated with IBAT inhibitors, suggests a US case series.
Countdown to AASLD 2025: A preview with Marlyn Mayo and Andreas Kremer
Dr Marlyn Mayo and Dr Andreas Kremer discuss what’s ahead at AASLD 2025, with a focus on advances in primary biliary cholangitis and primary sclerosing cholangitis. They share their perspectives on emerging research, key topics to watch, and what they are most looking forward to at this year’s meeting.
Countdown to AASLD 2025: A preview with Deepak Joshi and Silvia Vilarinho
Dr Deepak Joshi and Dr Silvia Vilarinho discuss what’s ahead at AASLD 2025, focusing on late-onset genetic cholestasis and Alagille syndrome, and share what they are most looking forward to at this year’s meeting.
Countdown to AASLD 2025: A preview with Marlyn Mayo and Andreas Kremer
Dr Marlyn Mayo and Dr Andreas Kremer discuss what’s ahead at AASLD 2025, with a focus on advances in primary biliary cholangitis and primary sclerosing cholangitis. They share their perspectives on emerging research, key topics to watch, and what they are most looking forward to at this year’s meeting.
IBAT inhibitor case studies point to adult intrahepatic cholestasis benefits
Ileal bile acid transporter inhibitors help treat adults with drug-induced or pregnancy-related intrahepatic cholestasis
Updates on IBAT inhibitors from EASL 2025
Dr Richard Thompson and Dr Verena Keitel-Anselmino discuss the latest updates on IBAT inhibitors from EASL 2025, including their potential use in PBC patients based on promising phase I and II trial results.
Odevixibat update for adult PFIC, older Alagille syndrome patients
Updated results for adult participants of the PEDFIC2 trial and older children taking part in the ASSERT-EXT study.
Unmet needs in late-onset genetic cholestasis: an expert discussion
This CME-accredited expert discussion aims to highlight the unmet needs in late-onset genetic cholestasis and provide guidance on the use of genetic testing in the diagnostic workup and initial management steps for the different genotypes, with reference to key trials and updates from The Liver Meeting 2024: American Association for the Study of Liver Diseases (AASLD).
IBAT trial updates confirm efficacy and safety for PFIC patients
Further findings on the efficacy and safety of ileal bile acid transporter inhibitors for patients with progressive familial intrahepatic cholestasis have been presented at the 2024 AASLD The Liver Meeting in San Diego, California, USA.
ABCB11 alteration linked to anabolic steroid-induced liver injury susceptibility
Dr Andrew Stolz reports on the relationship between alterations to the ABCB11 gene and the risk of drug-induced liver injury from anabolic steroids.
PFIC trial updates continue to support IBAT inhibitor efficacy and safety
Professor Richard Thompson shares his PFIC poster findings on the long-term efficacy and safety data of the PEDFIC 2 trial and the relationship between serum bile acid and event-free survival in the MARCH and MARCH-ON trials.
Oral contraceptive absorption unhindered by odevixibat in healthy women
Trial findings suggest that the IBAT inhibitor odevixibat does not prevent absorption of combined oral contraceptives in healthy women.
EASL guidelines direct genetic cholestatic liver management
An EASL expert panel has developed clinical practice guidelines for the management of progressive familial intrahepatic cholestasis and other genetic cholestatic liver diseases.
